Search the Newsreel

Citizens Jmp Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock

[10-Q] CHEVRON CORP Quarterly Earnings Report

ZVRA Looks 54.4% Undervalued on GF Value™ at $10.54

Zevra Therapeutics (NASDAQ: ZVRA) appears significantly undervalued according to GuruFocus' GF Value™, trading at $10.54, which is 54.4% below its intrinsic value estimate of $23.11. Despite strong Q2 2026 revenue growth driven by its product MIPLYFFA, the company's GF Score™ of 64/100 indicates moderate …

Zevra Therapeutics Reports Strong Q2 2026 Earnings with Growth in MIPLYFFA

Zevra Therapeutics announced robust Q2 2026 earnings, reporting $39.7 million in net revenue, a 53% year-over-year increase, largely driven by $30.2 million in U.S. sales of MIPLYFFA. The company also strengthened MIPLYFFA's intellectual property with an Orange Book listing extending to 2041. Despite strong …

XOM, CVX Stocks In Focus: Trump Criticizes Exxon And Chevron For Profiting From Iran-Driven Oil Price Surge — ‘They’re Making Too Much Money’

View Comments

Chevron (CVX) holder files to sell 5,547 common shares under Rule 144

An investor in Chevron (CVX) has filed to sell 5,547 common shares under Rule 144, valued at approximately $1,037,265.70, through Morgan Stanley Smith Barney LLC. The sale is projected for August 5, 2026, and the shares were acquired through restricted stock vesting and open-market …

Is Zevra Therapeutics Inc (ZVRA) Underperforming After Q2 2026 E

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) reported strong Q2 results, with earnings of $0.25 per share significantly beating the Zacks Consensus Estimate of $0.08, and revenues of $39.66 million surpassing estimates by 22.76%. Despite this positive performance and a 17.4% year-to-date stock increase, the company currently holds …

Zevra Therapeutics (ZVRA) Releases Q2 2026 Earnings: Revenue Growth and EPS Beat

ZEVRA THERAPEUTICS, INC. 2026: Revenue $39.66M, EPS $0.14— 10-Q Summary

Zevra Therapeutics, Inc. reported strong financial results for the quarter ended 2026, with revenue reaching $39.66M and diluted EPS of $0.14, primarily driven by the commercialization of MIPLYFFA. The company highlighted significant revenue growth, successful market penetration for MIPLYFFA, and ongoing progress in its …

Zevra Therapeutics, Inc. GAAP EPS of $0.14 beats by $0.03, revenue of $39.7M beats by $5.82M

* Zevra Therapeutics, Inc. press release [https://seekingalpha.com/pr/20608774-zevra-reports-second-quarter-2026-financial-results-and-corporate-update] (ZVRA [https://seekingalpha.com/symbol/ZVRA]): Q2 GAAP EPS of $0.14 beats by $0.03. * Revenue of $39.7M (+53.4% Y/Y) beats by $5.82M. * * Cash Position: Cash, cash equivalents and investments were $260.2 million as of June 30, 2026. Based …

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

Zevra Therapeutics reported strong second-quarter 2026 financial results, with $39.7 million in net revenue, a 53% increase over Q2 2025, primarily driven by MIPLYFFA sales. The company achieved a net income of $8.8 million and maintained a robust cash position of $260.2 million, which …

Evercore Inc. (NYSE: EVR) lifts H1 2026 EPS to $9.56 on advisory growth

Elevra Lithium Issues C$65m Convertible Notes to Fund North American Expansion

9 Stocks' Cash Flow Seen Blowing The Doors Off The S&P 500

Just like that, cash flow matters to S&P 500 investors. And it's becoming very apparent. Shares of the nine S&P 500 stocks expected to post the most free cash flow this year, like Micron and Chevron, are smashing the rest of the market. Continue …

Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

Zevra Therapeutics will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026, at 11:00 a.m. ET. Members of Zevra’s executive leadership team will deliver the presentation, and management will also be available for one-on-one meetings with registered conference …

Zevra Therapeutics (NASDAQ:ZVRA) Announces Quarterly Earnings Results

Q2 2026 Zevra Therapeutics Inc Earnings Call Transcript

Key Points Interested in Zevra Therapeutics, Inc.? Here are five stocks we like better. Revenue grew strongly: Zevra's Q2 2026 net revenue rose 53% year over year to $39.7 million, led by MIPLYFFA U.S. revenue of $30.2 million. Adjusted net income was $15.2 million, …

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) posts Q2 profit, repays debt

Chevron Q2 2026 Earnings: Record Production Drives a Sharp Profit Increase

Chevron reported a sharp increase in Q2 2026 earnings, with net income reaching $12.1 billion, driven by record production, higher commodity prices, and contributions from acquired Hess assets. The company's sales and operating revenues rose 51% to $67.2 billion, and diluted EPS increased significantly. …

Trump slams Exxon, Chevron for profits amid war

Former President Donald Trump criticized ExxonMobil and Chevron for their substantial profits, urging them to lower retail petrol prices and give back to the public. The oil companies reported combined profits of US$29 billion in the second quarter, more than triple the previous year, …

Should Chevron’s War-Boosted Margins and Cash Flows Prompt a Portfolio Rethink for (CVX) Investors?

In the past week, Chevron reported second-quarter 2026 results showing revenue rising to US$70.06 billion and net income to US$12.07 billion, alongside a maintained quarterly dividend of US$1.78 per share. The earnings surge, driven by higher production, early cost reductions and war-inflated refining margins, …

PR News | Chevron’s Sinclair Jumps to Northrop Grumman - Tue., Aug. 4, 2026

Randy Sinclair, who previously led investor relations at Chevron, is moving to Northrop Grumman as VP-IR, effective August 10. This move follows Northrop Grumman's recent $3 billion deal to accelerate the production of the Patriot anti-missile system. Sinclair brings 11 years of experience from …

Northrop names former Chevron investor relations head Randy Sinclair to lead IR (NOC:NYSE)

Northrop Grumman Corporation has appointed Randy Sinclair, formerly Chevron's investor relations head, as its new vice president of investor relations. Sinclair will report to CFO John Greene, with his appointment becoming effective on August 10.

Why Trump Has Blasted ExxonMobil (NYSE: XOM) And Chevron (NYSE: CVX) Over "Too Much Money"

President Donald Trump has publicly criticized ExxonMobil and Chevron for their excessive profits during the ongoing U.S.-led war against Iran. He called on the companies to reduce retail gasoline prices, arguing they are making "too much money" amid national strain. This rebuke comes as …

CVX Q2 Deep Dive: Production Gains, Cost Efficiencies, and New Energy Initiatives

Integrated energy company Chevron (NYSE:CVX) reported revenue ahead of Wall Street's expectations in Q2 CY2026, with sales up 56.3% year on year to $70.06 billion. Its non-GAAP profit of $6.06 per share was 8.8% above analysts' consensus estimates. Is now the time to buy …

Evercore (EVR) Stock Looks Reasonable On Fair Value Yet Rich On Earnings

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Evercore stock has delivered a strong 159.3% return over the past five years, yet the current checks send mixed valuation signals, with the …

Refiners Can't Deliver Gas Price Relief Trump Wants, Says Stephen Schork

Stephen Schork, principal and editor at The Schork Group, says refiners have virtually no ability to increase capacity and deliver more gasoline and diesel products and lower costs for consumers. President Donald Trump scolded ExxonMobil Holdings Corp. and Chevron Corp. Monday for making too …

Trump says oil companies Chevron and Exxon Mobil made ‘too much money’

Donald Trump criticized major oil companies Chevron and Exxon Mobil for making "too much money" due to high oil prices, urging them to reduce retail prices and give profits back to the public. He also stated that newly planned talks with Iran are its …

Zevra executives set to present at Boston growth conference

Zevra Therapeutics announced that its executive leadership team will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA, on Tuesday, August 11, 2026, at 11:00 a.m. ET. Management will also be available for one-on-one meetings, and a live webcast of the …

Evercore (EVR) Earnings And Senior Hire Put Its Undervalued View Back In Focus

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Evercore (EVR) just delivered a fresh set of second quarter 2026 earnings and confirmed its latest dividend, while also adding veteran equity capital markets banker Dylan Tornay …

Passive Income Play: Own This Many Chevron Shares for $1,000 a Year

This article highlights Chevron (NYSE: CVX) as a strong dividend stock for passive income. It details that owning approximately 144 shares, an investment of about $27,248, would generate $1,000 per year given its 3.67% yield. Chevron's consistent dividend growth over 39 years and diversified …

Evercore (EVR) Appoints Citi Veteran Dylan Tornay To Lead ECM Push

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Evercore appointed Dylan Tornay as Senior Managing Director in Equity Capital Markets. Tornay brings nearly 30 years of equity capital markets experience from Citi. …

JBH Investment Trust plans major Chevron (CVX) stock sale after prior large disposals

JBH Investment Trust, associated with Chevron Corporation, plans to sell 100,000 shares of Chevron common stock on or after August 3, 2026, through J.P. Morgan Securities LLC on the NYSE. This planned sale follows two significant disposals in May 2026, where the trust sold …

Chevron awards staff special bonus following earnings blowout

Chevron announced a special bonus for employees, equivalent to half a month's base pay, following a record earnings report boosted by high oil prices. CEO Mike Wirth cited successful cost-reduction, early Hess deal synergies, and safe operations despite geopolitical challenges. The announcement comes as …

Sponsors pushed for a bigger slice of continuation fund profits in H1

Jenna O'Malley/PitchBook News In the first half of 2026, a record number of private equity managers used continuation funds to return cash to their investors without having to sell companies. They also moved to capture a bigger slice of returns when that sale eventually …